Main Article Content


Background: Rheumatoid arthritis (RA) is a chronic, systemic disease characterized by inflammation and cellular proliferation in the synovial lining of joints that can ultimately result in cartilage and bone destruction.Patients with RA are at increased risk of osteoporotic fractures in both axial and appendicular bones. Several cytokines are involved in the pathogenesis of osteoporotic RA patients, including tumor necrosis factor α, interleukin (IL)-1, IL-6, and IL-17. Among these cytokines, IL-6 has a pivotal role in the pathogenesis of increased bone resorption in postmenopausal RA patients. There are currently scarce data concerning this process in premenopausal RA patients.

Objective: To determine the correlation of serum level IL-6 and disease activity with bone-resorption activity in premenopausal RA patients.

Methods: This is a cross-sectional study with consecutive sampling method conducted at the Division of Rheumatology, Cipto Mangunkusumo General Hospital from June until August 2010. Bone-resorption activity was quantified using serum C-terminal crosslinking telopeptide of type I collagen (CTx-I) level, while disease activity was assessed using the 28-joint disease activity (DAS28) score. Statistical analysis was performed to investigate the correlation of serum IL-6 level and disease activity with serum CTx-I level.

Results: There were 38 patients enrolled in this study. Mean serum level of IL-6 was 10.99 pg/mL (SD 16.06). Mean serum level of CTx-I was 405.37 pg/mL (SD 199.32). There was no significant correlation (p = 0.252) between serum IL-6 level with serum CTx-I level;
however, a significant correlation existed (r = 0.389, p = 0.033) among seropositive patients. There was no significant correlation (p = 0.257) between the DAS28
score with serum CTx-I level.

Conclusion: There were no significant correlation either of serum IL-6 level or disease activity with serum CTx-I level among patients in this study

Article Details

How to Cite
Akil, N., Isbagio, H., & Sumariyono, S. (2018). Correlation of serum level of interleukin-6 and disease activity with bone-resorption activity in premenopausal rheumatoid arthritis patients. Indonesian Journal of Rheumatology, 4(1).


  1. Park JY, Pillinger MH. Interleukin-6 in the pathogenesis of rheumatoid arthritis. Bull NYU Hosp Jt Dis 2007;65(Suppl 1):S4–10.
  2. Choy EHS, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907–16.
  3. Van Staa TP, Geusens P, Bijlsma JWJ, Leufkens HGM, Cooper C. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:3104–12.
  4. O’Dell JR. Therapeutic strategies for rheumatic arthritis. N Engl J Med 2004;350: 2591–602.
  5. Deane K. Increased prevalence translates into increased fractures—osteoporosis in RA: a common comorbidity. J Musculoskel Med 2006;23:838–44.
  6. Kawiyana S. Osteoporosis: pathogenesis, diagnosis, and recent update on the management [Osteoporosis: patogenesis, diagnosis, dan penanganan terkini] [Online] [cited 2010 Oct]. Available from: URL:
  7. Nanes MS. Tumor necrosis factor-alpha: molecular and cellular mechanisms in skeletal pathology. Gene 2003;321:1–15.
  8. Polzer K, Joosten L, Distler JH, Ruiz G, Baum W, Redlich K et al. Interleukin-1 is essential for systemic inflamatory bone loss. Ann Rheum Dis 2009;69:284–90.
  9. Palmqvist P, Persson E, Conaway HH, Lerner UH. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-ĸB ligand, osteoprotegerin, and receptor activator of NF-ĸB in mouse calvariae. J Immunol 2002;169:3353–62.
  10. Ding C, Parameswaran V, Udayan R, Burgess J, Jones G. Circulating level of nflammatory markers predict change in bone mineral density and resorption in older adults: a longitudinal study. J Clin Endocrinol Metab 2008;93:1952–8.
  11. Gaffen SL. Biology of recently discovered cytokines: Interleukin-17—a unique inflammatory cytokine with roles in bone biology and arthritis. Arthritis Res Ther2004;6: 240–7.
  12. Kawiyana S. High level of interleukin-6 as a risk factor for osteoporosis in estrogen-deficient postmenopausal women [Interleukin-6 yang tinggi sebagai faktor risiko terhadap kejadian osteoporosis pada wanita paska menopause defisiensi estrogen] [Online] [cited 2010 Oct]. Available from: URL:
  13. Vreugdenhil G, Löwenberg B, van Eijk HG, Swaak AJ. Anaemia of chronicdisease in rheumatoid arthritis. Raised serum interleukin-6 (IL-6) levelsand effects of IL-6 and anti-IL-6 on in vitro erythropoiesis. Rheumatol Int1990;10(3):127–30.
  14. Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 1998;128:127–37.
  15. Mamohara S, Okamoto H, Yago T, Furuya T, Nanke Y, Kotake S et al. The study of bone mineral density and bone turnover markers in postmenopausal women with active rheumatoid arthritis. Mod Rheumatol 2005;15:410–4.
  16. Gough AKS, Liley J, Eyre S, Holder RL, Emery P. Generalised bone loss inpatients with early rheumatoid arthritis. Lancet 1994;344:23–7.
  17. Smolen JS, Maini RN. Interleukin-6: a new therapeutic target. Arthritis Res Ther 2006;8(suppl 2):S5.
  18. Singer FR, Eyre DR. Using biochemical markers of bone turnover in clinical practice. Cleve Clin J Med 2008;75:739–50.
  19. Chapurlat RD, Garnelo P, Breart G, Meunier PJ, Delmas PD. Serum type I collagen break down product (serum Ctx) predicts hip fracture risk in elderly women: the EPIDOS study. Bone 2000;27:283–6.
  20. Aletaha D, Landewe R, Karonitsch T, Bathon J, Boers M, Bombardier C. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis 2008;67 :1360–4.
  21. DAS-Score [Online]. [cited 2010 Oct]; Available from: URL:
  22. Wislowska M, Jakubicz D, Stepien K, Cicha M. Serum concentrations of formation (PINP) and resorption (Ctx) bone turnover markers in rheumatoid arthritis. Rheumatol Int 2009;29:1403–9.
  23. Syversen SW, Goll GL, Van der Heijde D, Landewe R, Gaarder PI, OdegardS et al. Cartilage and bone biomarkers in rheumatoid arthritis: predictionof 10-year radiographic progression. J Rheumatol 2009;36:266–72.
  24. Knudsen LS, Hetland ML, Johansen JS, Skjodt H, Peters ND, Colic A et al. Changes in plasma IL-6, plasma VEGF and serum YKL-40 during treatment etanercept and methotrexate or etanercept alone in patients with active rheumatoid arthritis despite methotrexate therapy. Biomarker Insights 2009;4:91–5.
  25. Litinsky I, Paran D, Levartovsky D, Wigler I, Kaufman H, Yaron I et al. Theeffects of leflunomide on clinical parameters and serum levels of IL-6, IL-10, MMP-1 and MMP-3 in patients with resistant rheumatoid arthtritis. Cytokine 2006;33:106–10.
  26. Shingada A, Chewoolkar V, Bichile LS. Assessment of disease activity in rheumatoid arthritis using urinary CTx-I level as a marker of bone destruction and serum IL-6 as a marker of inflammation. Internet J Rheumatol [serial online] 2009 [cited 2010 Oct];6(1). Availablefrom: URL:
  27. Robak T, Gladalska A, Stepien H, Robak E. Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis. Mediat Inflamm 1996;5:435–41.
  28. Van Tuyl LHD, Felson DT, Wells G, Smolen J, Zhang B, Boers M. Evidence for predictive validity of remission on long-term outcome in rheumatoid arhtritis: a systematic review. Arthritis C Res 2010;62:108–17.
  29. Le Goff B, Blanchard, Berthelot JM, Heymann D, Maugars Y. Role for interleukin-6 in structural joint damage and systemic bone loss in rheumatoid arthritis. Joint Bone Spine 2010;77:201–5.
  30. Edwards CJ, Williams E. The role of interleukin-6 in rheumatoid arthritisassociated osteoporosis. Osteoporosis Int 2010;21:1287–93.
  31. Ferrari SL, Ahn-Luong L, Garnero P, Humphries SE, Greenspan SL. Two promoter polymorphisms regulating interleukin-6 gene expression are associated with circulating levels of c-reactive protein and markers of bone resorption in postmenopausal women. J Clin Endocrinol Metab
  32. ;88:255–9.
  33. Ranganathan P. Genetics of bone loss in rheumatoid arthritis-role of vitamin D receptor polymorphisms. Rheumatology 2009;48:342–6
  34. Steiner G. Autoantibodies: diagnostic helpers and pathogenetic players. In: Hochberg MC, Silman AJ, Smolen JS. Rheumatoid arthritis. Philadelphia: Mosby Elsevier; 2009. p. 180–90